Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey |
journalArticle |
2016 |
Gorphe, P.; Blanchard, P.; Moriniere, S.; Fakhry, N. |
Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice |
journalArticle |
2016 |
Michiels, S.; Ternes, N.; Rotolo, F. |
Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial |
journalArticle |
2015 |
Levy, A.; Azria, D.; Pignon, J. P.; Delarochefordiere, A.; Martel-Lafay, I.; Rio, E.; Malka, D.; Conroy, T.; Miglianico, L.; Becouarn, Y.; Malekzadeh, K.; Leclercq, J.; Juzyna, B.; Ezra, P.; Lemanski, C.; Deutsch, E. |
Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review |
journalArticle |
2015 |
Mamelle, E.; Borget, I.; Leboulleux, S.; Mirghani, H.; Suárez, C.; Pellitteri, P. K.; Shaha, A. R.; Hamoir, M.; Robbins, K. T.; Khafif, A.; Rodrigo, J. P.; Silver, C. E.; Rinaldo, A.; Ferlito, A.; Hartl, D. M. |
An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma |
journalArticle |
2016 |
Anota, A.; Boulin, M.; Dabakuyo-Yonli, S.; Hillon, P.; Cercueil, J. P.; Minello, A.; Jouve, J. L.; Paoletti, X.; Bedenne, L.; Guiu, B.; Bonnetain, F. |
Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy |
journalArticle |
2015 |
Blanchard, P.; Bakkour, M.; De Crevoisier, R.; Levy, A.; Baumert, H.; Patard, J. J.; Wibault, P.; Fizazi, K.; Bossi, A. |
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS) |
journalArticle |
2019 |
Adenis, A.; Bennouna, J.; Etienne, P. L.; Bogart, E.; Francois, E.; Galais, M. P.; Ben Abdelghani, M.; Michel, P.; Metges, J. P.; Dahan, L.; Conroy, T.; Ghiringhelli, F.; Drouillard, A.; El Hajbi, F.; Samalin, E.; Hiret, S.; Delaine-Clisant, S.; Mariette, C.; Penel, N.; Piessen, G.; Le Deley, M. C. |
Penalized Poisson model for network meta-analysis of individual patient time-to-event data |
journalArticle |
2021 |
OLLIER Edouard, Blanchard Pierre, LE TEUFF Gwénaël, MICHIELS Stefan |
Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors |
journalArticle |
2018 |
Koeppel, F.; Bobard, A.; Lefebvre, C.; Pedrero, M.; Deloger, M.; Boursin, Y.; Richon, C.; Chen-Min-Tao, R.; Robert, G.; Meurice, G.; Rouleau, E.; Michiels, S.; Massard, C.; Scoazec, J. Y.; Solary, E.; Soria, J. C.; André, F.; Lacroix, L. |
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene |
journalArticle |
2016 |
van Kempen, L. C.; Redpath, M.; Elchebly, M.; Klein, K. O.; Papadakis, A. I.; Wilmott, J. S.; Scolyer, R. A.; Edqvist, P. H.; Ponten, F.; Schadendorf, D.; van Rijk, A. F.; Michiels, S.; Dumay, A.; Helbling-Leclerc, A.; Dessen, P.; Wouters, J.; Stass, M.; Greenwood, C. M.; Ghanem, G. E.; van den Oord, J.; Feunteun, J.; Spatz, A. |
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma |
journalArticle |
2015 |
Hadoux, J.; Malka, D.; Planchard, D.; Scoazec, J. Y.; Caramella, C.; Guigay, J.; Boige, V.; Leboulleux, S.; Burtin, P.; Berdelou, A.; Loriot, Y.; Duvillard, P.; Chougnet, C. N.; Déandréis, D.; Schlumberger, M.; Borget, I.; Ducreux, M.; Baudin, E. |
Dose finding with longitudinal data: simpler models, richer outcomes |
journalArticle |
2015 |
Paoletti, X.; Doussau, A.; Ezzalfani, M.; Rizzo, E.; Thiebaut, R. |
Treatment challenges in and outside a network setting: Head and neck cancers |
journalArticle |
2018 |
Orlandi, E.; Alfieri, S.; Simon, C.; Trama, A.; Licitra, L. |
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors |
journalArticle |
2018 |
Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C. |
Brachytherapy: An overview for clinicians |
journalArticle |
2019 |
Chargari, C.; Deutsch, E.; Blanchard, P.; Gouy, S.; Martelli, H.; Guerin, F.; Dumas, I.; Bossi, A.; Morice, P.; Viswanathan, A. N.; Haie-Meder, C. |
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab |
journalArticle |
2016 |
Hua, C.; Boussemart, L.; Mateus, C.; Routier, E.; Boutros, C.; Cazenave, H.; Viollet, R.; Thomas, M.; Roy, S.; Benannoune, N.; Tomasic, G.; Soria, J. C.; Champiat, S.; Texier, M.; Lanoy, E.; Robert, C. |
Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort |
journalArticle |
2016 |
Blanchard, P.; Wong, A. J.; Gunn, G. B.; Garden, A. S.; Mohamed, A. S.; Rosenthal, D. I.; Crutison, J.; Wu, R.; Zhang, X.; Zhu, X. R.; Mohan, R.; Amin, M. V.; Fuller, C. D.; Frank, S. J. |
Preface |
journalArticle |
2016 |
Heinze, G.; Michiels, S.; Posch, M. |
[A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial] |
journalArticle |
2017 |
Blanchard, P.; Foulon, S.; Louvel, G.; Habibian, M.; Fizazi, K. |
The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence |
journalArticle |
2016 |
Ignatiadis, M.; Azim, H. A.; Desmedt, C.; Veys, I.; Larsimont, D.; Salgado, R.; Lyng, M. B.; Viale, G.; Leyland-Jones, B.; Giobbie-Hurder, A.; Kammler, R.; Dell'Orto, P.; Rothe, F.; Laios, I.; Ditzel, H. J.; Regan, M. M.; Piccart, M.; Michiels, S.; Sotiriou, C. |
Modalités de surveillance des patients suivis pour un cancer de la prostate avancé : résultats d’une enquête nationale de pratique |
journalArticle |
2016 |
Rozet, F.; Roupret, M.; Hennequin, C.; Massard, C.; Blanchard, P.; Le moulec, S. |
Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy |
journalArticle |
2018 |
Slimano, F.; Netzer, F.; Borget, I.; Lemare, F.; Besse, B. |
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease |
journalArticle |
2018 |
Danlos, F. X.; Voisin, A. L.; Dyevre, V.; Michot, J. M.; Routier, E.; Taillade, L.; Champiat, S.; Aspeslagh, S.; Haroche, J.; Albiges, L.; Massard, C.; Girard, N.; Dalle, S.; Besse, B.; Laghouati, S.; Soria, J. C.; Mateus, C.; Robert, C.; Lanoy, E.; Marabelle, A.; Lambotte, O. |
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience |
journalArticle |
2018 |
Fayard, F.; Petit, C.; Lacas, B.; Pignon, J. P. |
Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy |
journalArticle |
2017 |
Annede, P.; Seisen, T.; Klotz, C.; Mazeron, R.; Maroun, P.; Petit, C.; Deutsch, E.; Bossi, A.; Haie-Meder, C.; Chargari, C.; Blanchard, P. |
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer |
journalArticle |
2015 |
Burdett, S.; Pignon, J. P.; Tierney, J.; Tribodet, H.; Stewart, L.; Le Pechoux, C.; Aupérin, A.; Le Chevalier, T.; Stephens, R. J.; Arriagada, R.; Higgins, J. P.; Johnson, D. H.; Van Meerbeeck, J.; Parmar, M. K.; Souhami, R. L.; Bergman, B.; Douillard, J. Y.; Dunant, A.; Endo, C.; Girling, D.; Kato, H.; Keller, S. M.; Kimura, H.; Knuuttila, A.; Kodama, K.; Komaki, R.; Kris, M. G.; Lad, T.; Mineo, T.; Piantadosi, S.; Rosell, R.; Scagliotti, G.; Seymour, L. K.; Shepherd, F. A.; Sylvester, R.; Tada, H.; Tanaka, F.; Torri, V.; Waller, D.; Liang, Y. |
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer |
journalArticle |
2016 |
Michiels, S.; Pugliano, L.; Marguet, S.; Grun, D.; Barinoff, J.; Cameron, D.; Cobleigh, M.; Di Leo, A.; Johnston, S.; Gasparini, G.; Kaufman, B.; Marty, M.; Nekljudova, V.; Paluch-Shimon, S.; Penault-Llorca, F.; Slamon, D.; Vogel, C.; von Minckwitz, G.; Buyse, M.; Piccart, M. |
How individual participant data meta-analyses have influenced trial design, conduct, and analysis |
journalArticle |
2015 |
Tierney, J. F.; Pignon, J. P.; Gueffyier, F.; Clarke, M.; Askie, L.; Vale, C. L.; Burdett, S.; Cochrane, I. P. D. Meta-analysis Methods Group |
Precision medicine: lessons learned from the SHIVA trial - Authors' reply |
journalArticle |
2015 |
Le Tourneau, C.; Belin, L.; Paoletti, X.; Bieche, I.; Kamal, M. |
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort |
journalArticle |
2015 |
Chougnet, C. N.; Borget, I.; Leboulleux, S.; de la Fouchardiere, C.; Bonichon, F.; Criniere, L.; Niccoli, P.; Bardet, S.; Schneegans, O.; Zanetta, S.; Schvartz, C.; Drui, D.; Chauffert, B.; Rohmer, V.; Schlumberger, M. |
Nasopharyngeal carcinoma |
journalArticle |
2019 |
Chen, Y. P.; Chan, A. T. C.; Le, Q. T.; Blanchard, P.; Sun, Y.; Ma, J. |
Hypofractionation for prostate cancer: a word of caution |
journalArticle |
2016 |
Bossi, A.; Blanchard, P. |